These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28412971)

  • 21. Cohort study exploring the effect of lenvatinib on differentiated thyroid cancer.
    Tahara M; Takami H; Ito Y; Sugino K; Takahashi S; Takeyama H; Tsutsui H; Hara H; Mitsuma A; Yamashita H; Okamoto T; Sugitani I; Ohashi Y; Imai T
    Endocr J; 2018 Nov; 65(11):1071-1074. PubMed ID: 30369531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
    Tony M; Wagner M; Khoury H; Rindress D; Papastavros T; Oh P; Goetghebeur MM
    BMC Health Serv Res; 2011 Nov; 11():329. PubMed ID: 22129247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer.
    Hayato S; Shumaker R; Ferry J; Binder T; Dutcus CE; Hussein Z
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):971-978. PubMed ID: 30244318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
    Ye X; Zhu Y; Cai J
    J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenvatinib receives approval in DTC.
    J Nucl Med; 2015 Apr; 56(4):12N. PubMed ID: 25834176
    [No Abstract]   [Full Text] [Related]  

  • 26. Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data.
    Aydemirli MD; Kapiteijn E; Ferrier KRM; Ottevanger PB; Links TP; van der Horst-Schrivers ANA; Broekman KE; Groenwold RHH; Zwaveling J
    Eur J Endocrinol; 2020 Feb; 182(2):131-138. PubMed ID: 31751307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib.
    Fukuda N; Wang X; Ohmoto A; Urasaki T; Sato Y; Nakano K; Nishizawa M; Yunokawa M; Ono M; Tomomatsu J; Takahashi S
    In Vivo; 2020; 34(2):709-714. PubMed ID: 32111774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer.
    Berciano-Guerrero MÁ
    Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):40-46. PubMed ID: 36202609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer.
    Kiyota N; Schlumberger M; Muro K; Ando Y; Takahashi S; Kawai Y; Wirth L; Robinson B; Sherman S; Suzuki T; Fujino K; Gupta A; Hayato S; Tahara M
    Cancer Sci; 2015 Dec; 106(12):1714-21. PubMed ID: 26426092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem.
    Nervo A; Ragni A; Gallo M; Ferraris A; Fonio P; Piovesan A; Arvat E
    Thyroid; 2020 Feb; 30(2):229-236. PubMed ID: 31854230
    [No Abstract]   [Full Text] [Related]  

  • 31. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
    Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
    Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
    [No Abstract]   [Full Text] [Related]  

  • 32. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
    Wirth LJ; Durante C; Topliss DJ; Winquist E; Robenshtok E; Iwasaki H; Luster M; Elisei R; Leboulleux S; Tahara M
    Oncologist; 2022 Jul; 27(7):565-572. PubMed ID: 35482606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenvatinib: A Review in Refractory Thyroid Cancer.
    Frampton JE
    Target Oncol; 2016 Feb; 11(1):115-22. PubMed ID: 26867945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early prediction of lenvatinib treatment efficacy by using
    Takeuchi S; Shiga T; Hirata K; Taguchi J; Magota K; Ariga S; Gouda T; Ohhara Y; Homma R; Shimizu Y; Kinoshita I; Tsuji Y; Homma A; Iijima H; Tamaki N; Dosaka-Akita H
    BMJ Open; 2018 Aug; 8(8):e021001. PubMed ID: 30166292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study.
    Lee EK; Kim SM; Kim BH; Kim MJ; Lim DJ; Kim MH; Shin DY; Kang HC; Ahn BC; Kim SW; Ahn HY; Park YJ
    Thyroid; 2019 Dec; 29(12):1811-1819. PubMed ID: 31482759
    [No Abstract]   [Full Text] [Related]  

  • 36. Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients.
    Fukuda N; Toda K; Wang X; Ohmoto A; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
    Endocr J; 2021 Jun; 68(6):639-647. PubMed ID: 33504716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug safety evaluation of lenvatinib for thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer.
    Tahara M; Takami H; Ito Y; Okamoto T; Sugitani I; Sugino K; Takahashi S; Takeyama H; Tsutsui H; Hara H; Mitsuma A; Yamashita H; Ohashi Y; Imai T
    Thyroid; 2024 May; 34(5):566-574. PubMed ID: 38629757
    [No Abstract]   [Full Text] [Related]  

  • 40. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
    Wang E; Karedan T; Perez CA
    Anticancer Drugs; 2015 Aug; 26(7):689-97. PubMed ID: 25974026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.